Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice

NCT04647214 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT04647214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04647214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice
Lead sponsor
Allergan
Phase
Observational
Overall status
Completed
Start date
March 3, 2021
Completion date
July 12, 2024
Enrollment
220 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open-angle glaucoma